SCHEMBL19420175

SCHEMBL19420175

C#CCOc1c(I)cc(CO)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
HSD17B10 Q99714 2/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
BPTF Q12830 1/20 0.40
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.36
PTGS2 P35354 1/20 0.35
DRD2 P14416 1/20 0.34
MAPT P10636 1/20 0.33
MYB P10242 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15272453 0.81 PTGS2 (0.48) HSD17B10ALOX15TSHRBPTFALDH1A1
SCHEMBL29544982 0.77 SMN1; SMN2 (0.38) HTTHSD17B10ALOX15TSHRMGAM
SCHEMBL24805110 0.77 BPTF (0.46) HSD17B10ALOX15TSHRBPTFALDH1A1
SCHEMBL16774648 0.76 BPTF (0.71) HTTTSHRBPTFKMT2AMEN1
SCHEMBL19806084 0.74 PDE4B (0.47) HTTALDH1A1DRD2PDE4B
SCHEMBL29976179 0.74 PDE4B (0.47) HTTALDH1A1DRD2PDE4B
SCHEMBL19806086 0.74 POLB (0.52) HTTGAAKMT2AMEN1ALDH1A1
SCHEMBL28223321 0.73 MAPT (0.50) HSD17B10ALOX15TSHRKMT2AMEN1
SCHEMBL24106110 0.73 ALOX15 (0.47) HSD17B10ALOX15TSHRBPTFALDH1A1
SCHEMBL1122521 0.71 PTGS2 (0.64) HSD17B10ALOX15TSHRPTGS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 HTT 356/4885HSD17B10 2430/4885ALOX15 2055/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA HTT 368/4885HSD17B10 2186/4885ALOX15 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.